Toward therapnostic integration as a new paradigm for precision management of interstitial cystitis driven by medical-engineering convergence
Abstract
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a complex chronic inflammatory disease involving mucosal barrier defects, neurogenic inflammation, mast cell activation, and tissue remodeling. Current diagnosis lacks objective biomarkers, relying instead on symptom assessment and exclusion of confusable diseases. Cystoscopy is recommended for identifying Hunner lesions per ESSIC/AUA guidelines, and first-line intravesical GAG replacement therapies only achieve sustained response rates of 20-38% at 12 months. Medical-engineering integration and materials innovations propel IC management toward multi-scale regulation and intelligent repair. This article proposes intelligent materials and systems to advance IC from stepwise diagnosis to an integrated "sensing-feedback-execution" closed loop. At the diagnostic level, it integrates medical phenotyping with engineering multidimensional detection to construct a synergistic system of subjective symptoms, objective molecules, and physical function: attomolar long non-coding RNA(lncRNA) detection via CRISPR-graphene transistors, glycosaminoglycans (GAGs) quantification with 13C-FNDs, and real-time bladder monitoring with flexible electrodes and wireless sensing. At the therapeutic level, centering on targeted delivery, dynamic repair, functional remodeling, it integrates four pathways: inflammation-responsive engineered bacteria; DNA nanocages and dual-responsive hydrogels for precise release; bioprinted patches and digital…
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.